FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Eckardt

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
John R Eckardt; Joachim von Pawel; Jean-Louis Pujol; Zsolt Papai; Elisabeth Quoix; Andrea Ardizzoni; Ruth Poulin; Alaknanda J Preston; Graham Dane; Graham Ross
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
John R Eckardt; Joachim von Pawel; Zsolt Papai; Antoaneta Tomova; Valentina Tzekova; Theresa E Crofts; Sarah Brannon; Paul Wissel; Graham Ross
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
Lisa A Hammond; John R Eckardt; John Kuhn; Stanton L Gerson; Tom Johnson; Lon Smith; Ronald L Drengler; Elizabeth Campbell; Geoffrey R Weiss; Daniel Von Hoff; Eric K Rowinsky
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Eckardt (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: John R Eckardt; Joachim von Pawel; Jean-Louis Pujol; Zsolt Papai; Elisabeth Quoix; Andrea Ardizzoni; Ruth Poulin; Alaknanda J Preston; Graham Dane; Graham Ross
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2086-92.
2006: John R Eckardt; Joachim von Pawel; Zsolt Papai; Antoaneta Tomova; Valentina Tzekova; Theresa E Crofts; Sarah Brannon; Paul Wissel; Graham Ross
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):2044-51.
2004: Lisa A Hammond; John R Eckardt; John Kuhn; Stanton L Gerson; Tom Johnson; Lon Smith; Ronald L Drengler; Elizabeth Campbell; Geoffrey R Weiss; Daniel Von Hoff; Eric K Rowinsky
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1645-56.
1999: S Fields-Jones; A Koletsky; G Wilding; M O'Rourke; TJ O'Rourke; John R Eckardt; B Yates; C McGuirt; Howard A Burris
Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1307-10.
1999: Lisa A Hammond; John R Eckardt; Sharyn D Baker; S Gail Eckhardt; Margaret Dugan; K Forral; P Reidenberg; Paul Statkevich; Geoffrey R Weiss; David A Rinaldi; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2604-13.
1999: Carolyn D Britten; Eric K Rowinsky; Sharyn D Baker; S S Agarwala; John R Eckardt; RE Barrington; Sami Diab; Lisa A Hammond; T Johnson; Miguel A Villalona-Calero; U Fraass; Paul Statkevich; Daniel Von Hoff; S Gail Eckhardt
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1629-37.
1999: S Gail Eckhardt; Jinee Rizzo; K R Sweeney; Gillian F Cropp; Sharyn D Baker; Maura Kraynak; John Kuhn; Miguel A Villalona-Calero; L Hammond; Geoffrey Weiss; A Thurman; Lon Smith; Ronald L Drengler; John R Eckardt; Judy Moczygemba; Alison L Hannah; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1095-104.
1999: C J H Gerrits; J H M Schellens; Howard A Burris; John R Eckardt; A S T Planting; M E L van der Burg; Gladys I Rodriguez; Walter J Loos; V van Beurden; IR Hudson; Daniel Von Hoff; Jaap Verweij
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):69-75.
1998: Mace L Rothenberg; A Sharma; Geoffrey R Weiss; Miguel A Villalona-Calero; John R Eckardt; Cheryl Aylesworth; Maura Kraynak; David A Rinaldi; Gladys I Rodriguez; Howard A Burris; S Gail Eckhardt; CD Stephens; K Forral; S J Nicol; Daniel Von Hoff
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(7):733-8.
1998: Lisa A Hammond; John R Eckardt; R Ganapathi; Howard A Burris; G A Rodriguez; S Gail Eckhardt; Mace L Rothenberg; Geoffrey R Weiss; John Kuhn; S Hodges; Daniel Von Hoff; Eric K Rowinsky
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1459-67.
1998: C J H Gerrits; Howard A Burris; J H M Schellens; John R Eckardt; A S T Planting; M E L van der Burg; Gladys I Rodriguez; Walter J Loos; V van Beurden; IR Hudson; S Fields; Daniel Von Hoff; Jaap Verweij
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1153-8.
1998: S Gail Eckhardt; Sharyn D Baker; John R Eckardt; Thomas G Burke; D L Warner; John Kuhn; G Rodriguez; S Fields; A Thurman; Lon Smith; Mace L Rothenberg; L White; Paul Wissel; R Kunka; S DePee; D Littlefield; Howard A Burris; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):595-604.
1998: Gladys I Rodriguez; John Kuhn; Geoffrey R Weiss; Susan G Hilsenbeck; John R Eckardt; A Thurman; David A Rinaldi; S Hodges; Daniel Von Hoff; Eric K Rowinsky
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
Blood 1998;91(5):1533-41.
1998: Gladys I Rodriguez; John Kuhn; Geoffrey Weiss; P De La Cruz; Pamela New; S M Fields; John R Eckardt; L Campbell; G M Clark; Susan G Hilsenbeck; Daniel Von Hoff
A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion.
Investigational new drugs 1998;16(1):57-67.
1998: N W Peacock; Howard A Burris; V Dieras; L Smith; Gladys I Rodriguez; John R Eckardt; Suzanne F Jones; J Hardy; JA Hohneker; J Bigley; Daniel Von Hoff
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.
Investigational new drugs 1998;16(1):37-43.
1998: Miguel A Villalona-Calero; John R Eckardt; Howard A Burris; Maura Kraynak; S Fields-Jones; C Bazan; Jack Lancaster; T Hander; R Goldblum; L Hammond; A Bari; Ronald L Drengler; M Rothenberg; G Hadovsky; Daniel Von Hoff
A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):71-7.
1997: E Raymond; Howard A Burris; eric rowinsky; John R Eckardt; G Rodriguez; L Smith; G Weiss; Daniel Von Hoff
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):1003-8.
1997: Howard A Burris; V C Dieras; M Tunca; R H Earhart; John R Eckardt; Gladys I Rodriguez; D S Shaffer; S M Fields; Elizabeth Campbell; Larry J Schaaf; D Kasunic; Daniel Von Hoff
Phase I study with the DNA sequence-specific agent adozelesin.
Anti-cancer drugs 1997;8(6):588-96.
1997: Geert-Jan Creemers; C J H Gerrits; John R Eckardt; J H M Schellens; Howard A Burris; A S T Planting; Gladys I Rodriguez; Walter J Loos; IR Hudson; C Broom; Jaap Verweij; Daniel Von Hoff
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1087-93.
1996: S Gail Eckhardt; Howard A Burris; John R Eckardt; G Weiss; G Rodriguez; M Rothenberg; David A Rinaldi; R Barrington; John Kuhn; K Masuo; K Sudo; R Atsumi; T Oguma; L Higashi; S Fields; Leslie Ann Smetzer; Daniel Von Hoff
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(5):491-6.
1996: G R Weiss; D W Shaffer; C DeMoor; David A Rinaldi; Gladys I Rodriguez; John R Eckardt; C Stephens; Daniel Von Hoff
A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
Anti-cancer drugs 1996;7(4):402-9.
1996: Mace L Rothenberg; John R Eckardt; John Kuhn; Howard A Burris; James Nelson; Susan G Hilsenbeck; Gladys I Rodriguez; A M Thurman; L S Smith; S Gail Eckhardt; G R Weiss; Gary L Elfring; David A Rinaldi; Larry J Schaaf; Daniel Von Hoff
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1128-35.
1996: G R Weiss; H A Burris 3rd; John R Eckardt; S Gail Eckhardt; S M Fields; T O'Rourke; Gladys I Rodriguez; Mace L Rothenberg; A J Valley
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1996;16():132-67.
1995: John R Eckardt; G Eckhardt; Miguel A Villalona-Calero; Ronald L Drengler; Daniel Von Hoff
New anticancer agents in clinical development.
Oncology (Williston Park, N.Y.) 1995;9(12):1321-8; 1331; discussion 1332-4.
1995: Agop Bedikian; G R Weiss; Sewa S Legha; Howard A Burris; John R Eckardt; J Jenkins; Omar Eton; Antonio C Buzaid; Leslie Ann Smetzer; Daniel Von Hoff
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2895-9.
1995: John R Eckardt; G Eckhardt; Miguel A Villalona-Calero; Ronald L Drengler; Daniel Von Hoff
New anticancer agents in clinical development.
Oncology (Williston Park, N.Y.) 1995;9(11):1191-9.
1995: David A Rinaldi; Howard A Burris; F A Dorr; J R Woodworth; John Kuhn; John R Eckardt; G Rodriguez; S W Corso; S M Fields; C Langley
Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2842-50.
1995: G R Weiss; John Kuhn; Jinee Rizzo; L S Smith; Gladys I Rodriguez; John R Eckardt; Howard A Burris; S Fields; K VanDenBerg; Daniel Von Hoff
A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
Cancer chemotherapy and pharmacology 1995;35(5):397-402.
1994: John R Eckardt; E Campbell; Howard A Burris; G R Weiss; Gladys I Rodriguez; S M Fields; A M Thurman; N W Peacock; P Cobb; Mace L Rothenberg
A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon.
American journal of clinical oncology 1994;17(6):498-501.
1994: Howard A Burris; A Awada; John Kuhn; John R Eckardt; P W Cobb; David A Rinaldi; S Fields; L Smith; Daniel Von Hoff
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Anti-cancer drugs 1994;5(4):394-402.
1994: John R Eckardt; Daniel Von Hoff
New drugs in clinical development in the United States.
Hematology/oncology clinics of North America 1994;8(2):305-32.
1994: John R Eckardt; Howard A Burris; John Kuhn; MC Bissery; M Klink-Alakl; Gary M Clark; Daniel Von Hoff
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Journal of the National Cancer Institute 1994;86(1):30-3.
1994: Daniel Von Hoff; Howard A Burris; John R Eckardt; M Rothenberg; S M Fields; S F Chen; John Kuhn
Preclinical and phase I trials of topoisomerase I inhibitors.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S41-5.
1994: G R Weiss; Howard A Burris; John R Eckardt; S Fields; T O'Rourke; Gladys I Rodriguez; Mace L Rothenberg
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1994;15():130-51.
1993: D W Shaffer; L S Smith; Howard A Burris; G M Clark; John R Eckardt; S M Fields; G R Weiss; David A Rinaldi; K J Bowen; John Kuhn
A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
Cancer research 1993;53(24):5929-33.
1993: Mace L Rothenberg; John Kuhn; Howard A Burris; James Nelson; John R Eckardt; M Tristan-Morales; Susan G Hilsenbeck; G R Weiss; L S Smith; Gladys I Rodriguez
Phase I and pharmacokinetic trial of weekly CPT-11.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2194-204.
1993: Howard A Burris; R Irvin; John Kuhn; S Kalter; L Smith; D Shaffer; S Fields; Geoffrey Weiss; John R Eckardt; G Rodriguez
Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):950-8.
1993: John R Eckardt; David G Roodman; D H Boldt; G M Clark; R Alvarez; C Page; H Gaskill; Charles F LeMaistre
Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT.
Bone marrow transplantation 1993;11(2):125-31.
1993: G R Weiss; Howard A Burris; John R Eckardt; S Fields; R Johnson; T O'Rourke; Gladys I Rodriguez; Mace L Rothenberg; J Wall
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1993;14():118-28.
1992: T D Brown; Howard A Burris; John R Eckardt; T J O'Rourke; Gladys I Rodriguez; J G Wall; G R Weiss
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1992;13():115-55.